Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00392327 · OUTCOME

Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET · Source last updated 2026-06-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent Probability
Interval / dispersion
95% Confidence Interval
Time frame
Up to 5 years

What was measured

The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact.

Analysis population: Eligible SPNET patients are included.

Groups in this outcome

Regimen A (SPNET Patients)

SPNET patients who received regimen A (no carboplatin / no isotretinoin)

Regimen B (SPNET Patients)

SPNET patients who received regimen B (carboplatin / no isotretinoin)

Regimen C (SPNET Patients)

SPNET patients who received regimen C (no carboplatin / isotretinoin)

Regimen D (SPNET Patients)

SPNET patients who received regimen D (carboplatin / isotretinoin)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen A (SPNET Patients)23
Regimen B (SPNET Patients)19
Regimen C (SPNET Patients)21
Regimen D (SPNET Patients)22

Reported measurements

Source class 1
Values in Percent Probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen A (SPNET Patients)60.9Not reported41.780.1Not reported
Regimen B (SPNET Patients)57.9Not reported35.880.0Not reported
Regimen C (SPNET Patients)35.3Not reported15.754.9Not reported
Regimen D (SPNET Patients)77.0Not reported59.494.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        41.7
        upper Limit
        80.1
        value
        60.9
      2. group Id
        OG001
        lower Limit
        35.8
        upper Limit
        80.0
        value
        57.9
      3. group Id
        OG002
        lower Limit
        15.7
        upper Limit
        54.9
        value
        35.3
      4. group Id
        OG003
        lower Limit
        59.4
        upper Limit
        94.6
        value
        77.0
denoms
  1. counts
    1. group Id
      OG000
      value
      23
    2. group Id
      OG001
      value
      19
    3. group Id
      OG002
      value
      21
    4. group Id
      OG003
      value
      22
    units
    Participants
description
The Kaplan-Meier method will be used to estimate 5-year OS, defined as the time from study enrollment to death from any cause, or to date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    SPNET patients who received regimen A (no carboplatin / no isotretinoin)
    id
    OG000
    title
    Regimen A (SPNET Patients)
  2. description
    SPNET patients who received regimen B (carboplatin / no isotretinoin)
    id
    OG001
    title
    Regimen B (SPNET Patients)
  3. description
    SPNET patients who received regimen C (no carboplatin / isotretinoin)
    id
    OG002
    title
    Regimen C (SPNET Patients)
  4. description
    SPNET patients who received regimen D (carboplatin / isotretinoin)
    id
    OG003
    title
    Regimen D (SPNET Patients)
param Type
NUMBER
population Description
Eligible SPNET patients are included.
reporting Status
POSTED
time Frame
Up to 5 years
title
Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
type
SECONDARY
unit Of Measure
Percent Probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice